Creative Biogene Unveils Comprehensive Services of Bacterial Genome Editing

Creative Biogene unveils its comprehensive services of bacterial genome editing for worldwide pharmaceutical partners after the self-optimization of homologous recombination technology and the CRISPR/Cas9 platform.

New York, USA – March 30, 2022 – Having been engaged in the field of bacterial gene-editing over years, Creative Biogene enjoys deep expertise in diverse microbes and excels in various gene-editing techniques. Based on its optimal CRISPR/Cas9 genome editing platform and mature homologous recombination technology, Creative Biogene can provide satisfactory bacterial genome editing services in compliance with the gold standards.

To conduct genome editing in bacteria, a series of genetic methods such as suicide plasmids have been developed. However, these technologies are laborious and multi-step. In this regard, the current state-of-the-art approach is to combine homologous recombination of a DNA template with DNA targeting by programmable nucleases from the CRISPR/Cas systems. On the one hand, the CRISPR/Cas is a strong microbial adaptive immune system due to its simplicity and programmability. On the other hand, homologous recombination occurs naturally in eukaryotic organisms, bacteria, and certain viruses and is a powerful tool in genetic engineering.

Strengthened by years of experience in bacterial mutant library construction, homologous recombination, and CRISPR genetic modification, Creative Biogene has matured to the position of bacterial gene-editing expert. According to the characteristics of different bacteria, the scientist team can dynamically develop a specific CRISPR/Cas9 system and combine different homologous recombination approaches, e.g., Red/ET system-based and temperature-sensitive plasmids-based methods, to meet the requirements of genome modification, such as knockout, replacement, insertion, or site-directed mutation.

As a genome editing expert, Creative Biogene successfully assists its industrial partners in achieving gene modification in plenty of bacteria like escherichia coli, lactococcus lactis, bacillus licheniformis as well as other difficult-to-modify bacteria, demonstrating its strength in growing bacterial gene-editing portfolio in this area. From project evaluation to final delivery, the company can guarantee customers high-quality edited strain and detailed experiment reports under strict quality control (QC) and quality assurance (QA). Importantly, its newly optimized CRISPR/Cas9 platform can avoid many laborious experimental procedures, which helps researchers simplify their bacterial studies to a large extent.

“The modification of the bacterial genome helps us understand the pathogenic mechanism of pathogenic bacteria, the mechanism of drug resistance, and eliminate drug-resistant bacteria. However, we realize the genome editing of different bacteria could be tricky sometimes.” Said the director of the Bacteria Department, “Our homologous recombination technology and CRISPR/Cas9 system are rather mature after years of development. We can modify general bacteria and specific ones required by our clients.”

About Creative Biogene

Creative Biogene is a high-tech service company that specializes in microbiological research-related issues. Creative Biogene supplies customers with an overall microbiological research program: including sample collection, preservation methods, preliminary experiments and effect evaluation, experiments and data analysis, etc. Creative Biogene is dedicated to assisting researchers in exploring the hidden mysteries between microbes and health, production, and the environment to make better use of microbial resources.

Media Contact
Company Name: Creative Biogene
Contact Person: Marcia Brady
Email: Send Email
Phone: 1-631-386-8241
Country: United States
Website: https://www.microbialtec.com